ss-31
SS-31, explained.
SS-31 (elamipretide) is a synthetic four-amino-acid peptide studied in mitochondrial biology, and recently the first mitochondria-targeted therapy to receive a narrow FDA approval. This page is a neutral overview of what it is, how it is understood to work, and its regulatory status — educational only, not medical advice.
Educational only — not medical advice. Consult a qualified licensed provider.
SS-31 (elamipretide) is a synthetic four-amino-acid peptide that concentrates inside mitochondria and binds cardiolipin, a phospholipid of the inner mitochondrial membrane. In September 2025 it received a narrow FDA approval for the rare Barth syndrome only; every other application, including longevity, remains investigational and is not FDA-approved. Material sold as 'SS-31 research chemical' is not the approved drug. This page is neutral education, not medical advice.
What SS-31 is
SS-31 is a synthetic tetrapeptide — just four amino acids — better known by its drug name elamipretide (with development codes MTP-131 and Bendavia, and the brand FORZINITY). What distinguishes it from most peptides is its mitochondrial targeting: an alternating aromatic-and-cationic design, including an unusual residue called 2',6'-dimethyltyrosine, lets it cross cell membranes and accumulate inside the inner mitochondrial membrane without depending on the membrane's electrical charge. SS-31 has been through formal clinical development, and in September 2025 it received an FDA approval — the first ever for a mitochondria-targeted drug. That approval is narrow: it covers only the ultra-rare Barth syndrome. Anything sold simply as 'SS-31 research chemical' is not that regulated product and is not FDA-approved for any use.
How SS-31 works
Mitochondria are the energy-producing organelles inside cells, and their inner membranes are folded into structures called cristae where energy is generated. SS-31's central described action is binding cardiolipin — a phospholipid found almost exclusively in that inner mitochondrial membrane. By associating with cardiolipin, SS-31 is thought to help hold the cristae in their proper shape, and this cardiolipin-binding step is the best-established part of its proposed mechanism. Better-organized cristae are hypothesized to support a more efficient electron-transport chain and steadier ATP production (the cell's energy currency). In laboratory and animal studies it has also been reported to reduce markers of oxidative stress and to help normalize mitochondrial shape and quality control in disease models. The downstream energy and antioxidant effects are characterized largely in preclinical work and remain under investigation in humans.
Areas of research interest
- Barth syndrome — the basis of its narrow FDA approval, studied in patients under clinical supervision
- Mitochondrial myopathy — investigated in clinical trials such as MMPOWER-3, where primary endpoints were mixed or negative
- Heart failure — studied in trials such as PROGRESS-HF; benefit not established
- Dry age-related macular degeneration and other retinal disease — examined in the ReCLAIM program; investigational
- General longevity and aging biology — a frequently discussed research rationale around 'mitochondrial support,' with minimal human evidence
Safety & legal status
In clinical trials the most commonly reported adverse effects were injection-site reactions — redness, itching, and pain at the site — alongside generally mild events such as headache and nausea. Because every application outside Barth syndrome is investigational, the long-term safety of off-label use is not established, and 'research-chemical' SS-31 is not the regulated drug, so its identity and purity can vary. On the regulatory side: on 2025-09-19 the FDA granted accelerated approval to elamipretide (FORZINITY) for Barth syndrome only — continued approval may depend on a confirmatory trial — while all other uses, including longevity, remain investigational, off-label, and not FDA-approved. None of this is medical advice; consult a qualified licensed provider about your own situation and follow the FDA label and prescriber guidance for the approved product.
SS-31 vs other mitochondrial compounds
| SS-31 (elamipretide) | MOTS-c | NAD+ | |
|---|---|---|---|
| What it is | Synthetic mitochondria-targeting tetrapeptide | Mitochondrial-derived signaling peptide | Coenzyme / supplement |
| Described mechanism | Binds cardiolipin; associated with inner-membrane stabilization | Studied as an AMPK-activating metabolic signal | Studied as a coenzyme in cellular energy and repair pathways |
| Regulatory status | FDA-approved (Barth syndrome only); otherwise investigational, not FDA-approved | Investigational / research-only; not FDA-approved | Sold as a supplement; investigational by route |
| Research areas | Mitochondrial disease; aging biology (off-label) | Metabolic and exercise-physiology research | Cellular energy and 'mitochondrial support' research |
Frequently asked
What are SS-31's reported side effects?+
In clinical trials the most commonly reported were injection-site reactions — redness, itching, and pain — plus generally mild events such as headache and nausea. Because non-Barth uses are investigational, the long-term safety of off-label use is not established, and unregulated research-chemical material adds quality and identity uncertainty on top.
Is SS-31 a steroid?+
No. SS-31 (elamipretide) is a synthetic four-amino-acid peptide that targets mitochondria and binds cardiolipin. It is not an anabolic steroid and is structurally and mechanistically unrelated to one.
Is SS-31 FDA approved?+
Only narrowly. The FDA granted accelerated approval in September 2025 to elamipretide (FORZINITY) for Barth syndrome, making it the first mitochondria-targeted therapy approved. Every other use, including longevity, remains investigational, off-label, and not FDA-approved, and research-chemical SS-31 is not the approved drug.
What does SS-31 research focus on?+
Beyond its approved use in Barth syndrome, SS-31 has been studied in mitochondrial myopathy, heart failure, and retinal disease, with mixed or negative trial results, and is discussed in aging-biology research around mitochondrial function. These are research areas, not established outcomes, and none of this is medical advice.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more